CHTR three-lens brief
Evidence-based stock research on CHTR. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Price down 25.50% in the last session — a material single-day move. · Trading at 1% of its 52-week range — deep in the lower band.
- Price down 25.50% in the last session — a material single-day move.
- Trading at 1% of its 52-week range — deep in the lower band.
- RSI at 29 — technically oversold.
- Underperforming SPY by 23.4pp over 30 days.
- P/E of 4.9 — trading at a value multiple.
CHTR closed at $180.13 (-25.50%) as of 2026-04-25. Market cap: $25.43B. P/E (trailing) 4.9. Positives: p/E of 4.9 — trading at a value multiple.; analyst mean target $274.13 — 52% above current (15 analysts).. Concerns: price down 25.50% in the last session — a material single-day move.; trading at 1% of its 52-week range — deep in the lower band.. Last quarter: Revenue $13.60B, net income $1.16B, free cash flow $3.29B.
Why three lenses on CHTR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CHTRacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CHTR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CHTR brief"></iframe>